SPY424.48-0.78 -0.18%
DIA343.41-0.89 -0.26%
IXIC14,072.86-101.29 -0.71%

Earnings Outlook for Halozyme Therapeutics

On Monday, May 10, Halozyme Therapeutics (NASDAQ:HALO) will release its latest earnings report. Here is Benzinga's outlook for the company.

05/07/2021 10:07

On Monday, May 10, Halozyme Therapeutics (NASDAQ:HALO) will release its latest earnings report. Here is Benzinga's outlook for the company.

Net Income, Earnings, And Earnings Per Share

Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.

Earnings And Revenue

Analysts predict Halozyme Therapeutics will report earnings of $0.32 per share on revenue of $84.88 million. Halozyme Therapeutics EPS in the same period a year ago totaled $0.04. Sales were $25.35 million.

What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter?

Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values.

The Wall Street estimate would represent a 900.0% increase in the company's earnings. Sales would be up 234.78% from the year-ago period. In comparison to analyst estimates in the past, here is how the company's reported EPS stacks up:

Quarter Q4 2021 Q3 2020 Q2 2020 Q1 2020
EPS Estimate 0.53 0.20 0.25 -0.02
EPS Actual 0.50 0.25 0.19 -0.04
Revenue Estimate 120.16 M 60.91 M 66.68 M 42.96 M
Revenue Actual 121.70 M 65.32 M 55.22 M 25.35 M

eps graph

Stock Performance

Shares of Halozyme Therapeutics were trading at $47.69 as of May 06. Over the last 52-week period, shares are up 94.68%. Given that these returns are generally positive, long-term shareholders are probably content going into this earnings release.

Do not be surprised to see the stock move on comments made during its conference call. Halozyme Therapeutics is scheduled to hold the call at 16:30:00 ET and can be accessed here.